CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer's disease.

By K. Buerger, Michael Ewers, T. Pirttilä, R. Zinkowski, I. Alafuzoff, Stefan J. Teipel, J. Debernardis, D. Kerkman, Cheryl McCulloch, Hilkka Soininen and 1 more. Brain : a journal of neurology, 2006

624 citations recorded by the source corpus.

Subfields: Cognitive Neuroscience, Physiology, Psychiatry and Mental health

View Paper: https://www.semanticscholar.org/paper/9ce88783b6ded6fbb7dc83b88f100e53edaa020c

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cognitive Neuroscience

In Physiology

In Psychiatry and Mental health

Citations in the corpus

NIA-AA Research Framework: Toward a biological definition of Alzheimer’s disease (2018, neutral): “The level of CSF P-tau also does correlate with severity of PHF tau accumulation after death [81,150].”
Preclinical Alzheimer’s disease: Definition, natural history, and diagnostic criteria (2016, background): “This suggests that in AD, CSF tau changes may not only be considered as nonspecific (downstream) markers of neuronal death, as seen in other neurodegenerative diseases [60], but also as a more-specific pathophysiological marker of AD in relation to neurofibrillary tangles [61,62].”
Role of neuroinflammation in neurodegeneration development (2023, result): “In line with these results, many studies have suggested that both the total tau and phosphorylated tau are increased in the CSF of R47H carrying AD patients compared with non-carriers,(202) and the increasing of tau in CSF can be attributed to the pathology burden of tau in the brain.(203) In additi”
Tau phosphorylation: the therapeutic challenge for neurodegenerative disease. (2009, background): “The concentration of phosphorylated T231 in cerebrospinal fluid is associated with increased neurofibrillary tangle load in AD, and a deficit in Pin1 results in neurodegeneration, together indicating that phosphorylation at this residue might be significant in AD pathogenesis[ 12 ].”
A/T/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers (2016, background): “23–25 Biomarkers of tau pathology (neurofibrillary tangles) are elevated CSF phosphorylated tau (p-tau) and tau PET.24,26 Biomarkers of AD-like neurodegeneration or neuronal injury are CSF total tau (t-tau), [18F]fluorodeoxyglucose (FDG)-PET hypometabolism, and atrophy on structural MRI in regions c”
Biomarkers for Alzheimer's disease: current status and prospects for the future (2018, background): “In addition, several studies also show correlations between neuritic plaque counts and higher CSF T-tau (32) and P-tau (67) levels.”